ADME (absorption, distribution, metabolism, excretion): The real meaning-avoiding disaster and maintaining efficacy for preclinical candidates

Katherine Tsaioun, Steven A. Kates

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The purpose of preclinical Absorption, Distribution, Metabolism, Excretion, and Toxicity also referred to as early drug metabolism and pharmacokinetics is to reduce the risk of drug development to avoid spending scarce resources on weak lead candidates and expensive R&D programs and clinical trials. This allows drug-development resources to be focused on fewer, but more-likely-to-succeed drug candidates. This chapter provides the rationale for effective preclinical drug development using a systematic approach to limit failure.

Original languageEnglish (US)
Title of host publicationTranslational Stroke Research
Subtitle of host publicationFrom Target Selection to Clinical Trials
PublisherSpringer New York
Pages617-638
Number of pages22
ISBN (Electronic)9781441995308
ISBN (Print)9781441995292
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Tsaioun, K., & Kates, S. A. (2012). ADME (absorption, distribution, metabolism, excretion): The real meaning-avoiding disaster and maintaining efficacy for preclinical candidates. In Translational Stroke Research: From Target Selection to Clinical Trials (pp. 617-638). Springer New York. https://doi.org/10.1007/978-1-4419-9530-8_30